ERVEBO is a vaccine to prevent disease caused by Zaire ebolavirus in individuals who are 18 years of age and older. The vaccine helps to protect the patient from getting Ebola virus disease caused by one type of Ebola virus. After receiving FDA approval for the Ebola vaccine Ervebo in 2019, Merck is poised to eradicate the deadly virus. The company figured out how to scale the manufacturing of the inoculation, which consists of a genetically engineered live virus that triggers an immune response. They delivered more than 250,000 doses to the Democratic Republic of Congo, where it reduced mortality by at least 88% among people exposed to the virus.